The effectiveness of monotherapy with PI3K/AKT/mTOR pathway inhibitors in ovarian cancer: A meta-analysis

P. van der Ploeg*, A. Uittenboogaard, A.M.J. Thijs, H.M. Westgeest, I.A. Boere, S. Lambrechts, A. van de Stolpe, R.L.M. Bekkers, J.M.J. Piek

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)433-444
Number of pages12
JournalGynecologic Oncology
Volume163
Issue number2
DOIs
Publication statusPublished - 1 Nov 2021

Keywords

  • Ovarian cancer
  • Phosphatidylinositol-3-kinase
  • Akt
  • Mammalian target of rapamycin
  • Signal transduction pathway
  • Targeted therapy
  • ADVANCED SOLID TUMORS
  • PHASE-I
  • PI3K PATHWAY
  • EPITHELIAL OVARIAN
  • DOSE-ESCALATION
  • 1ST-IN-HUMAN
  • TRIAL
  • MULTICENTER
  • MTOR
  • TEMSIROLIMUS

Cite this